Spire Healthcare Group (LON:SPI) Trading Down 18.1% on Analyst Downgrade

Spire Healthcare Group plc (LON:SPI) was down 18.1% on Thursday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 320 to GBX 300. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Spire Healthcare Group traded as low as GBX 169 ($2.18) and last traded at GBX 183.80 ($2.38). Approximately 5,375,384 shares traded hands during mid-day trading, an increase of 704% from the average daily volume of 668,624 shares. The stock had previously closed at GBX 224.50 ($2.90).

Spire Healthcare Group Stock Performance

The company has a debt-to-equity ratio of 62.25, a quick ratio of 0.74 and a current ratio of 0.70. The company has a market capitalization of £711.58 million, a price-to-earnings ratio of 25.22, a P/E/G ratio of 1.06 and a beta of 0.96. The firm has a 50-day simple moving average of GBX 227.28 and a two-hundred day simple moving average of GBX 229.74.

Spire Healthcare Group (LON:SPI) last announced its quarterly earnings data on Thursday, March 6th. The company reported GBX 8.80 ($0.11) earnings per share for the quarter. Spire Healthcare Group had a net margin of 1.96% and a return on equity of 3.82%. On average, sell-side analysts anticipate that Spire Healthcare Group plc will post 15.6634747 EPS for the current fiscal year.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.